Table 2.

Selected Pharmacodynamic Parameters for the Currently Available Glycoprotein IIb/IIIa Antagonists

Agent	Molecule	Mechanism of IIb/IIIa Receptor Blockade	Specificity	Biologic Half-Life (h)	Restoration of Normal Hemostatic Function (h)	Reversibility	Clearance	Dose	Dose Adjustment in Renal Insufficiency	Provoke Antibody Response
Abciximab	Monoclonal antibody	Agent binding causes steric hindrance and conformational changes	+++	8–12	72	Platelets	Platelet binding, protease degradation	0.25 mg/kg bolus followed by 0.125 μg/kg/min infusion for 12 h	No	Yes
Eptifibatide	Peptide	Mimics native protein sequence in receptor	+++	2.5	3–4	Time	Renal (98%), partially metabolized	180 μg/kg bolus followed by 2.0 μg/kg/min infusion and additional 180 μg/kg bolus 10 minutes after first bolus for 18–24 h	Yes	Yes or no???
Tirofiban	Nonpeptide	Mimics native protein sequence in receptor	+++	2	4	Time	Renal (60–70%), Biliary (20–30%)	0.10 μg/kg bolus followed by 0.10 μg/kg/min infusion for 18–24 h	Yes	Yes or no??